114 related articles for article (PubMed ID: 25791160)
21. Overexpressions of miR-212 are associated with poor prognosis of patients with pancreatic ductal adenocarcinoma.
Wu Z; Zhou L; Ding G; Cao L
Cancer Biomark; 2017; 18(1):35-39. PubMed ID: 27814273
[TBL] [Abstract][Full Text] [Related]
22. The State of the Art on Blood MicroRNAs in Pancreatic Ductal Adenocarcinoma.
Gao Z; Jiang W; Zhang S; Li P
Anal Cell Pathol (Amst); 2019; 2019():9419072. PubMed ID: 31583198
[TBL] [Abstract][Full Text] [Related]
23. Identification of candidate biomarkers and analysis of prognostic values in ovarian cancer by integrated bioinformatics analysis.
Xu Z; Zhou Y; Cao Y; Dinh TL; Wan J; Zhao M
Med Oncol; 2016 Nov; 33(11):130. PubMed ID: 27757782
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis.
Bloomston M; Frankel WL; Petrocca F; Volinia S; Alder H; Hagan JP; Liu CG; Bhatt D; Taccioli C; Croce CM
JAMA; 2007 May; 297(17):1901-8. PubMed ID: 17473300
[TBL] [Abstract][Full Text] [Related]
25. Four potential microRNAs affect the progression of pancreatic ductal adenocarcinoma by targeting MET via the PI3K/AKT signaling pathway.
Yao LC; Jiang XH; Yan SS; Wang W; Wu L; Zhai LL; Xiang F; Ji T; Ye L; Tang ZG
Oncol Lett; 2021 Apr; 21(4):326. PubMed ID: 33692858
[TBL] [Abstract][Full Text] [Related]
26. Identification of key regulators of pancreatic cancer progression through multidimensional systems-level analysis.
Rajamani D; Bhasin MK
Genome Med; 2016 May; 8(1):38. PubMed ID: 27137215
[TBL] [Abstract][Full Text] [Related]
27. Cell-free plasma microRNA in pancreatic ductal adenocarcinoma and disease controls.
Carlsen AL; Joergensen MT; Knudsen S; de Muckadell OB; Heegaard NH
Pancreas; 2013 Oct; 42(7):1107-13. PubMed ID: 24048453
[TBL] [Abstract][Full Text] [Related]
28. ARHGEF15 overexpression worsens the prognosis in patients with pancreatic ductal adenocarcinoma through enhancing the motility and proliferative activity of the cancer cells.
Fukushima H; Yasumoto M; Ogasawara S; Akiba J; Kitasato Y; Nakayama M; Naito Y; Ishida Y; Okabe Y; Yasunaga M; Horiuchi H; Sakamoto E; Itadani H; Mizuarai S; Oie S; Yano H
Mol Cancer; 2016 May; 15(1):32. PubMed ID: 27145964
[TBL] [Abstract][Full Text] [Related]
29. Identification of microRNA biomarkers in the blood of breast cancer patients based on microRNA profiling.
Zhang K; Wang YW; Wang YY; Song Y; Zhu J; Si PC; Ma R
Gene; 2017 Jul; 619():10-20. PubMed ID: 28359916
[TBL] [Abstract][Full Text] [Related]
30. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
31. Identification and interaction analysis of key genes and microRNAs in hepatocellular carcinoma by bioinformatics analysis.
Mou T; Zhu D; Wei X; Li T; Zheng D; Pu J; Guo Z; Wu Z
World J Surg Oncol; 2017 Mar; 15(1):63. PubMed ID: 28302149
[TBL] [Abstract][Full Text] [Related]
32. miRNA: A Diagnostic and Therapeutic Tool for Pancreatic Cancer.
Qadir MI; Faheem A
Crit Rev Eukaryot Gene Expr; 2017; 27(3):197-204. PubMed ID: 29199604
[TBL] [Abstract][Full Text] [Related]
33. Specific MAPK-Associated MicroRNAs in Serum Differentiate Pancreatic Cancer from Autoimmune Pancreatitis.
Akamatsu M; Makino N; Ikeda Y; Matsuda A; Ito M; Kakizaki Y; Saito Y; Ishizawa T; Kobayashi T; Furukawa T; Ueno Y
PLoS One; 2016; 11(7):e0158669. PubMed ID: 27380024
[TBL] [Abstract][Full Text] [Related]
34. Global Analysis of miRNA-mRNA Interaction Network in Breast Cancer with Brain Metastasis.
Li Z; Peng Z; Gu S; Zheng J; Feng D; Qin Q; He J
Anticancer Res; 2017 Aug; 37(8):4455-4468. PubMed ID: 28739740
[TBL] [Abstract][Full Text] [Related]
35. Circulating microRNAs in serum of human K-ras oncogene transgenic rats with pancreatic ductal adenocarcinomas.
Yabushita S; Fukamachi K; Tanaka H; Sumida K; Deguchi Y; Sukata T; Kawamura S; Uwagawa S; Suzui M; Tsuda H
Pancreas; 2012 Oct; 41(7):1013-8. PubMed ID: 22513294
[TBL] [Abstract][Full Text] [Related]
36. Identification of biological targets of therapeutic intervention for diabetic nephropathy with bioinformatics approach.
Wu T; Li Q; Wu T; Liu HY
Exp Clin Endocrinol Diabetes; 2014 Nov; 122(10):587-91. PubMed ID: 25003364
[TBL] [Abstract][Full Text] [Related]
37. Serum level of co-expressed hub miRNAs as diagnostic and prognostic biomarkers for pancreatic ductal adenocarcinoma.
Su Q; Zhu EC; Qu YL; Wang DY; Qu WW; Zhang CG; Wu T; Gao ZH
J Cancer; 2018; 9(21):3991-3999. PubMed ID: 30410604
[No Abstract] [Full Text] [Related]
38. Elevated miR-483-3p expression is an early event and indicates poor prognosis in pancreatic ductal adenocarcinoma.
Wang C; Sun Y; Wu H; Yu S; Zhang L; Meng Y; Liu M; Yang H; Liu P; Mao X; Lu Z; Chen J
Tumour Biol; 2015 Dec; 36(12):9447-56. PubMed ID: 26124009
[TBL] [Abstract][Full Text] [Related]
39. Identification of key microRNAs and genes in preeclampsia by bioinformatics analysis.
Luo S; Cao N; Tang Y; Gu W
PLoS One; 2017; 12(6):e0178549. PubMed ID: 28594854
[TBL] [Abstract][Full Text] [Related]
40. Integrated analysis of mRNA and miRNA expression profiles in pancreatic ductal adenocarcinoma.
Sun H; Zhao L; Pan K; Zhang Z; Zhou M; Cao G
Oncol Rep; 2017 May; 37(5):2779-2786. PubMed ID: 28339085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
